Birgitta Sparre

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

Charlott Brunmark, Anna Runström, Lennart Ohlsson et al. · Journal of Neuroimmunology · 2002 · 165 citations

Immunogenetics, Autoimmune Disease, Immunology +8

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR‐215757), a new quinoline‐3‐carboxamide derivative: Studies in lupus‐prone mice and a multicenter, randomized, double‐blind, placebo‐controlled, repeat‐dose, dose‐ranging study in patients with systemic lupus erythematosus

Anders Bengtsson, Gunnar Sturfelt, Christian Lood et al. · Arthritis & Rheumatism · 2011 · 121 citations

Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis

Martin Stenström, Helén Nyhlén, Marie Törngren et al. · Journal of Dermatological Science · 2016 · 49 citations · Full text

CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THE METABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR

Helén Tuvesson, Ingrid Hallin, Robert Persson et al. · Drug Metabolism and Disposition · 2005 · 37 citations

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

Roger Hesselstrand, Jörg H. W. Distler, Gabriela Riemekasten et al. · Arthritis Research & Therapy · 2021 · 36 citations · Full text